Trial Profile

Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eliglustat (Primary) ; Imiglucerase (Primary)
Indications Gaucher's disease type I; Gaucher's disease type III
Focus Adverse reactions; Pharmacokinetics; Registrational
Acronyms ELIKIDS
Sponsors Sanofi; Sanofi Genzyme

Most Recent Events

12 Mar 2023 This study has been completed in Sweden, According to European Clinical Trials Database.
12 Mar 2023 This study has been completed in Sweden, According to European Clinical Trials Database.
12 Aug 2022 Planned End Date changed from 1 Nov 2025 to 20 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com